research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
Search
forResearch
5 / 1000+ results 
research MULTIOMICS – A NEW EXCITING ERA OF RESEARCH
In this study, researchers at the Laboratory of Regenerative Medicine WUM are exploring the long-term effects of SARS-CoV-19 infection, focusing on stem cell mobilization and engraftment processes, and utilizing advanced diagnostic techniques to develop algorithms for rare disease classification, including amyloidosis.
research A NEW GENERATION OF MARKERS FOR CANCER DETECTION AND DRUG TRANSPORT
This study reported the development of fluorescent markers using wide band gap metal oxides with rare earth ions for early tumor detection and treatment. Testing in animals showed high efficiency and selectivity, with potential applications in contrast-enhanced MRI, targeted drug delivery, and photodynamic cancer therapy.
research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.
research BRAIN HEALTH SERVICES – A NEW APPROACH TO PREVENTING ALZHEIMER’S DISEASE
This study discusses the need for better organization and specialized services in Alzheimer's prevention, focusing on modifiable factors like hearing impairment, vascular risk, and lifestyle habits, and highlights challenges and opportunities from the two-year experience of Brain Health services at Karolinska Institutet in Sweden.
Community Join
5 / 1000+ resultscommunity FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
community New warning by FDA on topical finasteride
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
community Finasteride alternative close to fda approval in the US
Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.
community No more hair transplants - a new FDA-cleared fractional laser treatment called FoLix
A new FDA-cleared fractional laser treatment called FoLix is discussed as a potential alternative to hair transplants, but users express skepticism due to its high cost, pain, and lack of proven results. Some users prefer traditional methods like Minoxidil, finasteride, steroid shots, and microneedling for hair growth.
Learn
— no results
Experts
— no results
Clinics
— no results